A Multiple-Site, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) Study to Assess the Safety and Tolerability of Inhaled SNSP113 in Healthy Male Subjects (Part A) and Subjects With Stable Cystic Fibrosis (Part B)

Trial Profile

A Multiple-Site, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) Study to Assess the Safety and Tolerability of Inhaled SNSP113 in Healthy Male Subjects (Part A) and Subjects With Stable Cystic Fibrosis (Part B)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Oct 2017

At a glance

  • Drugs SYGN 113 (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Synspira
  • Most Recent Events

    • 12 Oct 2017 Status changed from planning to recruiting.
    • 29 Jun 2017 Acoording to Synspira Media Release, this trail will initiate in early 2018.
    • 10 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top